Patel Anand C, Van Natta Mark L, Tonascia James, Wise Robert A, Strunk Robert C
Division of Allergy/Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, and St Louis Children's Hospital, St Louis, Mo.
Childhood Asthma Management Program Coordinating Center, the Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
J Allergy Clin Immunol. 2008 Oct;122(4):781-787.e8. doi: 10.1016/j.jaci.2008.08.010.
Assessment of asthma through spirometric analysis in children is challenging because of often normal FEV(1) values.
We used Mead's slope ratio (SR; (dV /dV)/(V /V)) to analyze the shape of the flow-volume loop.
We analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily.
In the placebo group both SR61 and SR35 improved over time. Bronchodilator consistently improved both SR61 and SR35, without change in degree of improvement over time. Similarly, in the budesonide group time and bronchodilator each independently improved both SR61 and SR35. At 4 months and the end of the study, patients receiving budesonide had significant improvements in SR61 relative to patients receiving placebo, which was independent of bronchodilator effect. Budesonide and placebo were not different with respect to prebronchodilator or postbronchodilator SR35.
Budesonide-treated patients have less concave flow-volume loops when compared with placebo-treated patients. Time and bronchodilator also make the flow-volume loop less concave. Furthermore, it appears that there are discrete bronchodilator- and corticosteroid-responsive components of airflow obstruction in pediatric asthma.
由于儿童的第一秒用力呼气容积(FEV₁)值通常正常,通过肺量计分析评估哮喘具有挑战性。
我们使用米德斜率比(SR;(dV /dV)/(V /V))来分析流速-容积环的形状。
我们分析了时间、沙丁胺醇和布地奈德对基线、4个月时以及研究结束时儿童哮喘管理项目队列中接受每日两次吸入安慰剂或布地奈德治疗的参与者呼气早期(用力肺活量(FVC)的75%至50%之间,SR61)和晚期(FVC的75%至50%之间,SR35)的FEV₁、FEV₁/用力肺活量(FVC)比值、25%至75%呼气容积的用力呼气流量以及米德SR的影响。
在安慰剂组中,SR61和SR35均随时间改善。支气管扩张剂持续改善SR61和SR35,且改善程度不随时间变化。同样,在布地奈德组中,时间和支气管扩张剂各自独立地改善SR61和SR35。在4个月和研究结束时,接受布地奈德治疗的患者相对于接受安慰剂治疗的患者,SR61有显著改善,这与支气管扩张剂的作用无关。布地奈德组和安慰剂组在支气管扩张剂使用前或使用后的SR35方面无差异。
与安慰剂治疗的患者相比,布地奈德治疗的患者流速-容积环的凹陷程度较小。时间和支气管扩张剂也会使流速-容积环的凹陷程度减小。此外,小儿哮喘气流阻塞似乎存在离散的支气管扩张剂和皮质类固醇反应性成分。